SI0959888T1 - Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease - Google Patents
Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's diseaseInfo
- Publication number
- SI0959888T1 SI0959888T1 SI9730230T SI9730230T SI0959888T1 SI 0959888 T1 SI0959888 T1 SI 0959888T1 SI 9730230 T SI9730230 T SI 9730230T SI 9730230 T SI9730230 T SI 9730230T SI 0959888 T1 SI0959888 T1 SI 0959888T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical composition
- alzheimer
- disease
- manufacture
- treatment
- Prior art date
Links
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005228 clioquinol Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000002738 chelating agent Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR96100286 | 1996-08-13 | ||
| PCT/IB1997/000983 WO1998006403A1 (en) | 1996-08-13 | 1997-08-08 | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
| EP97932969A EP0959888B1 (en) | 1996-08-13 | 1997-08-08 | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI0959888T1 true SI0959888T1 (en) | 2002-10-31 |
Family
ID=10942479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9730230T SI0959888T1 (en) | 1996-08-13 | 1997-08-08 | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6001852A (cs) |
| EP (1) | EP0959888B1 (cs) |
| JP (1) | JP2000516606A (cs) |
| KR (1) | KR100489969B1 (cs) |
| CN (1) | CN1114407C (cs) |
| AT (1) | ATE205086T1 (cs) |
| AU (1) | AU720643B2 (cs) |
| BR (1) | BR9711194A (cs) |
| CA (1) | CA2264097C (cs) |
| CZ (2) | CZ292411B6 (cs) |
| DE (1) | DE69706566T2 (cs) |
| DK (1) | DK0959888T3 (cs) |
| ES (1) | ES2162319T3 (cs) |
| HU (1) | HUP9903906A3 (cs) |
| IL (1) | IL128416A (cs) |
| IS (1) | IS1907B (cs) |
| NO (1) | NO316768B1 (cs) |
| NZ (1) | NZ334124A (cs) |
| PL (1) | PL188838B1 (cs) |
| PT (1) | PT959888E (cs) |
| RU (1) | RU2193406C2 (cs) |
| SI (1) | SI0959888T1 (cs) |
| SK (1) | SK283117B6 (cs) |
| TR (1) | TR199900293T2 (cs) |
| WO (1) | WO1998006403A1 (cs) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
| CN1145482C (zh) | 1997-08-21 | 2004-04-14 | P·N·杰罗里马托斯有限公司 | 泛喹酮在治疗阿尔茨海默氏病中的用途 |
| AU760140B2 (en) * | 1997-10-24 | 2003-05-08 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| US5994323A (en) * | 1997-12-31 | 1999-11-30 | P.N. Gerolymatos S.A. | Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof |
| US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
| US20050112543A1 (en) * | 1998-03-11 | 2005-05-26 | The General Hospital Corporation | Method of screening for drugs useful in treating Alzheimer's disease |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6638711B1 (en) | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
| EP1140090B1 (en) | 1999-01-07 | 2004-12-22 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment or prevention of memory impairment |
| US6692234B2 (en) | 1999-03-22 | 2004-02-17 | Water Management Systems | Pump system with vacuum source |
| CN1422269A (zh) * | 2000-02-09 | 2003-06-04 | 北陆制药株式会社 | 1h－咪唑并吡啶衍生物 |
| FR2818551B1 (fr) * | 2000-12-22 | 2007-06-01 | Claude Marc Pierre Hannoun | Utilisation de chelateurs pour le traitement des maladies a prions |
| US6803379B2 (en) * | 2002-06-04 | 2004-10-12 | Jose A. Fernandez-Pol | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| JP4690043B2 (ja) | 2002-10-04 | 2011-06-01 | プラナ バイオテクノロジー リミティッド | 神経に対し活性な化合物 |
| US20080063599A1 (en) * | 2002-11-18 | 2008-03-13 | Jorge Setoain Quinquer | Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils |
| WO2004087160A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| MXPA06005743A (es) * | 2003-11-19 | 2007-04-17 | Acrux Dds Pty Ltd | Metodo y composicion para el tratamiento o profilaxis de trastornos de amiloidosis. |
| US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
| AU2005227420B2 (en) * | 2005-10-14 | 2013-05-09 | Alltech, Inc. | Method and compositions for altering cell function |
| US8871715B2 (en) | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
| US8865763B2 (en) | 2005-10-14 | 2014-10-21 | Alltech, Inc. | Methods and compositions for altering cell function |
| EP1954718B1 (en) * | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| US8497072B2 (en) * | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
| JP5290147B2 (ja) | 2006-04-14 | 2013-09-18 | プラナ バイオテクノロジー リミティッド | 加齢黄斑変性症（ａｍｄ）の処置方法 |
| MY153248A (en) * | 2006-07-14 | 2015-01-29 | Ac Immune Sa | Humanized antibody against amyloid beta |
| WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| RU2338542C1 (ru) * | 2007-03-20 | 2008-11-20 | Игорь Анатольевич Помыткин | Применение воды с пониженным содержанием дейтерия для приготовления средств лечения нейродегенеративных заболеваний и улучшения когнитивной функции |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| SI2238166T1 (sl) | 2007-10-05 | 2014-03-31 | Genentech, Inc. | Uporaba protitelesa proti amiloidu beta pri očesnih bolezni |
| ES2332687B1 (es) * | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
| CA2806909C (en) | 2010-07-30 | 2019-12-17 | Ac Immune S.A. | Safe and functional humanized antibodies |
| FR2966827B1 (fr) | 2010-10-27 | 2014-08-22 | Kimonella Ventures Ltd | Compose peptidique utile pour l'inhibition de la formation de plaques amyloides |
| JP6153179B2 (ja) * | 2013-04-02 | 2017-06-28 | アンジー ファーマスーティカル シーオー．，エルティーディー．Ａｎｎｊｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 抗神経変性剤としての多機能キノリン誘導体 |
| US11844774B2 (en) | 2014-04-24 | 2023-12-19 | Omoidesouzou Co., Ltd. | Amyloid fiber formation limiter or inhibitor |
| KR20160057500A (ko) * | 2014-11-05 | 2016-05-24 | 아카데미아 시니카 | 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE393238C (de) * | 1923-05-12 | 1924-03-31 | Maschb Akt Ges H Flottmann & C | Bohrhammer |
| US3174899A (en) * | 1960-12-30 | 1965-03-23 | Ciba Geigy Corp | Composition for the management of post antibiotic enteritis |
| US3178343A (en) * | 1962-11-27 | 1965-04-13 | Ciba Geigy Corp | Pharmaceutical compositions and method of using same |
| DE1617417A1 (de) * | 1966-12-08 | 1971-03-25 | Ciba Geigy | Pharmazeutisches Praeparat |
| RU2057531C1 (ru) * | 1986-07-01 | 1996-04-10 | Всероссийский научный центр по безопасности биологически активных веществ | Средство для стимуляции обучения и памяти |
| DE3932338A1 (de) * | 1989-09-28 | 1991-04-11 | Nmi Naturwissenschaftl U Mediz | Verfahren zur praeventiven therapie von morbus alzheimer |
| GB9010039D0 (en) * | 1990-05-03 | 1990-06-27 | Reckitt & Colmann Prod Ltd | Medicament preparation |
| GB9108080D0 (en) * | 1991-04-15 | 1991-06-05 | Smithkline Beecham Plc | Pharmaceutical composition |
| US5206264A (en) * | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| EP0613560B2 (en) * | 1991-11-12 | 2006-06-21 | Prana Biotechnology Ltd | A method for assaying and treating alzheimer's disease |
| US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| AU1831195A (en) * | 1994-01-13 | 1995-08-01 | Research Foundation For Mental Hygiene, Inc. | Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders |
| WO1995031199A1 (en) * | 1994-05-11 | 1995-11-23 | P.N. Gerolymatos S.A. | Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases |
| US5505958A (en) * | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
-
1997
- 1997-08-08 CZ CZ1999484A patent/CZ292411B6/cs not_active IP Right Cessation
- 1997-08-08 AT AT97932969T patent/ATE205086T1/de not_active IP Right Cessation
- 1997-08-08 PT PT97932969T patent/PT959888E/pt unknown
- 1997-08-08 TR TR1999/00293T patent/TR199900293T2/xx unknown
- 1997-08-08 RU RU99105213/14A patent/RU2193406C2/ru not_active IP Right Cessation
- 1997-08-08 CN CN97197919A patent/CN1114407C/zh not_active Expired - Fee Related
- 1997-08-08 BR BR9711194-5A patent/BR9711194A/pt not_active Application Discontinuation
- 1997-08-08 NZ NZ334124A patent/NZ334124A/xx unknown
- 1997-08-08 WO PCT/IB1997/000983 patent/WO1998006403A1/en active IP Right Grant
- 1997-08-08 KR KR10-1999-7001196A patent/KR100489969B1/ko not_active Expired - Fee Related
- 1997-08-08 EP EP97932969A patent/EP0959888B1/en not_active Expired - Lifetime
- 1997-08-08 ES ES97932969T patent/ES2162319T3/es not_active Expired - Lifetime
- 1997-08-08 IL IL12841697A patent/IL128416A/en not_active IP Right Cessation
- 1997-08-08 HU HU9903906A patent/HUP9903906A3/hu unknown
- 1997-08-08 JP JP10509541A patent/JP2000516606A/ja active Pending
- 1997-08-08 DE DE69706566T patent/DE69706566T2/de not_active Expired - Lifetime
- 1997-08-08 CA CA002264097A patent/CA2264097C/en not_active Expired - Fee Related
- 1997-08-08 PL PL97331822A patent/PL188838B1/pl not_active IP Right Cessation
- 1997-08-08 AU AU36324/97A patent/AU720643B2/en not_active Ceased
- 1997-08-08 DK DK97932969T patent/DK0959888T3/da active
- 1997-08-08 CZ CZ2003491A patent/CZ295118B6/cs not_active IP Right Cessation
- 1997-08-08 SI SI9730230T patent/SI0959888T1/xx unknown
- 1997-08-08 SK SK179-99A patent/SK283117B6/sk not_active IP Right Cessation
-
1998
- 1998-02-13 US US09/023,544 patent/US6001852A/en not_active Expired - Lifetime
-
1999
- 1999-02-09 NO NO19990595A patent/NO316768B1/no not_active Application Discontinuation
- 1999-02-10 IS IS4972A patent/IS1907B/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI0959888T1 (en) | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| HUP0000558A3 (en) | Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| GB9103764D0 (en) | Compositions | |
| IL134263A0 (en) | Use of phanquinone for the treatment of alzheimer's disease | |
| BG102667A (en) | Diosgenine-containing composition | |
| MX9707642A (es) | Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos. | |
| DK0583026T3 (cs) | ||
| IL105475A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS | |
| AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
| AUPP823999A0 (en) | A treatment | |
| BG106151A (en) | Pharmaceutical complex | |
| UA29461C2 (uk) | Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу | |
| HUP9802536A3 (en) | Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer | |
| ZA924128B (en) | New combination preparations for treatment of Parkinson's disease. | |
| NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
| GEP20094628B (en) | (s,s)-reboxetine for treating fibromyalgia and other somatoform disorders | |
| MX9709684A (es) | Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel. |